Related references
Note: Only part of the references are listed.Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment
Eddy Pasquier et al.
Oncotarget (2015)
Chemoresistance to Temozolomide in Human Glioma Cell Line U251 is Associated with Increased Activity of O 6-methylguanine-DNA Methyltransferase and Can be Overcome by Metronomic Temozolomide Regimen
Qiang Pan et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2012)
Metronomic Chemotherapy with the COMBAT Regimen in Advanced Pediatric Malignancies: A Multicenter Experience
D. Zapletalova et al.
ONCOLOGY (2012)
Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera?
Raffaele Addeo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Nontoxic, Fiscally Responsible, Future of Oncology: Could it be Beginning in the Third World?
Giannoula Lakka Klement et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2011)
Metronomic chemotherapy: new rationale for new directions
Eddy Pasquier et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics
C. Meille et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2008)
Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens
Qingyu Zhou et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
The anti-angiogenic basis of metronomic chemotherapy
RS Kerbel et al.
NATURE REVIEWS CANCER (2004)
Inhibition of angiogenesis by non-toxic doses of temozolomide
H Kurzen et al.
ANTI-CANCER DRUGS (2003)
Minimizing long-term tumor burden: The logic for metronomic chemotherapeutic dosing and its antiangiogenic basis
P Hahnfeldt et al.
JOURNAL OF THEORETICAL BIOLOGY (2003)
Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly
JY Wang et al.
ANTI-CANCER DRUGS (2003)
Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors
JC Panetta et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2003)
Temozolomide in malignant gliomas of childhood: A United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup study
LS Lashford et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Redefining the target: Chemotherapeutics as antiangiogenics
KD Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Docetaxel administered on a weekly basis for metastatic breast cancer
HJ Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
